Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × tagraxofusp × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04317781 2024-07-31

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 8 charts
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡